Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Banco de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Food Chem Toxicol ; 44(11): 1875-83, 2006 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-16904806

RESUMEN

The objective of this study was to investigate the hypolipidemic effects of powdered whole persimmon leaf supplement in rats fed high-fat diet. Three groups of male Sprague-Dawley rats during 6 weeks were fed different diet: normal control (NC), high-fat (HF), and high-fat supplemented with powdered whole persimmon leaf (PL; 5%, wt/wt) groups. Body weight and relative weight of interscapular brown adipose tissue were significantly lower in the PL group than in the HF group, while plasma leptin concentration was higher. The supplementation of persimmon leaf significantly lowered the plasma total cholesterol and triglyceride concentrations, whereas elevated the ratio of HDL-C/total-C and improved the atherogenic index. Persimmon leaf supplementation led the hepatic cholesterol and triglyceride values to similar levels to the NC group. Accumulation of hepatic lipid droplets and the epididymal white adipocyte size of PL group were diminished comparing to the HF group. Hepatic HMG-CoA and ACAT activities were significantly higher in the PL group than in other groups. Contents of fecal triglyceride, cholesterol and acidic sterol were significantly higher in the PL group than in the HF group. Accordingly, we suggest that supplementation of the powdered whole persimmon leaf improves plasma and hepatic lipid levels profile partly via the increased fecal lipids in high-fat fed rats. These beneficial effects may be due to the properties of its phenolic compounds (1.15 g/100g) and high fiber (63.48 g/100g) content in the powdered persimmon leaf.


Asunto(s)
Grasas de la Dieta/administración & dosificación , Diospyros/química , Hipolipemiantes/farmacología , Metabolismo de los Lípidos/efectos de los fármacos , Extractos Vegetales/farmacología , Aumento de Peso/efectos de los fármacos , Acilcoenzima A/metabolismo , Tejido Adiposo Pardo/efectos de los fármacos , Animales , Colesterol/sangre , Colesterol/metabolismo , Modelos Animales de Enfermedad , Epidídimo/efectos de los fármacos , Epidídimo/patología , Lipoproteínas/sangre , Lipoproteínas/efectos de los fármacos , Hígado/efectos de los fármacos , Hígado/metabolismo , Hígado/patología , Masculino , Tamaño de los Órganos/efectos de los fármacos , Hojas de la Planta/química , Ratas , Ratas Sprague-Dawley , Esterol O-Aciltransferasa/metabolismo , Triglicéridos/metabolismo
2.
Food Chem Toxicol ; 48(8-9): 2298-303, 2010.
Artículo en Inglés | MEDLINE | ID: mdl-20573577

RESUMEN

Anti-atherogenic effect of ferulic acid (0.02%, w/w) was investigated in comparison with the clofibrate (0.02%, w/w) in apolipoprotein E-deficient (apo E(-/-)) mice fed Western diet. Concentrations of total cholesterol (total-C), apolipoprotein B (apo B) in the plasma and epididymal adipose tissue weight were significantly lower in the ferulic acid and clofibrate supplemented groups compared to the control group. The ratio of apo B to apo A-I was also significantly lower in those groups than in the control group. Activities of hepatic ACAT and HMG-CoA reductase were only significantly lower in the ferulic acid and clofibrate groups, respectively than in the control group. The numbers of mice that exhibited aortic fatty plaque were 8/10 in control groups vs. 0/10 in the ferulic acid or clofibrate group. The activities of anti-oxidant enzymes (superoxide dismutase, catalase, glutathione peroxidase, glutathione reductase and paraoxonase) in the hepatocyte and erythrocyte were significantly higher in the ferulic acid group than in the control group. In contrast, hepatic TBARS level was only markedly lower in the ferulic acid group. These results provide a new insight into the anti-atherogenic property of ferulic acid in the apo E(-/-) mice fed a Western diet.


Asunto(s)
Anticolesterolemiantes/farmacología , Apolipoproteínas E/genética , Aterosclerosis/prevención & control , Clofibrato/farmacología , Ácidos Cumáricos/farmacología , Dieta , Tejido Adiposo/efectos de los fármacos , Animales , Antioxidantes/farmacología , Apolipoproteínas E/fisiología , Arildialquilfosfatasa/metabolismo , Aterosclerosis/patología , Ingestión de Alimentos/efectos de los fármacos , Hidroximetilglutaril-CoA Reductasas/metabolismo , Peroxidación de Lípido/efectos de los fármacos , Lípidos/sangre , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Tamaño de los Órganos/efectos de los fármacos , Esterol O-Aciltransferasa/metabolismo , Aumento de Peso/efectos de los fármacos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA